UY30830A1 - Piperidinas sustituidas que presentan actividad inhibitoria de proteinquinasa - Google Patents
Piperidinas sustituidas que presentan actividad inhibitoria de proteinquinasaInfo
- Publication number
- UY30830A1 UY30830A1 UY30830A UY30830A UY30830A1 UY 30830 A1 UY30830 A1 UY 30830A1 UY 30830 A UY30830 A UY 30830A UY 30830 A UY30830 A UY 30830A UY 30830 A1 UY30830 A1 UY 30830A1
- Authority
- UY
- Uruguay
- Prior art keywords
- substituted
- proteinquinasa
- piperidins
- presenting
- inhibitory activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Abstract
La invencion proporciona compuestos inhibidores de quinasas PKA y PKB de formula I o sales, solvatos, tautomeros o N-oxidos del mísmo, donde E es un anillo heteroarilo de cinco miembros conteniendo 1, 2, 4 o 4 heteroatomos seleccionados de O, N y S siempre que no más de un heteroátomo sea distinto de N; cada q y r son 0 o 1 ; siempre que q+r sea 1 o 2; T es N o un grupo CR5; J1- J2 es N=C(R6), (R7)C=N, (R8)N-C(O), (R8)2C-C(O), N=N o (R7)C=C(R6), Q3 es un enlace o un grupo hidrocarburo C1-C3 enlazador saturado opcionalmente sustituido por fluoro e hidroxi ; G es NR2R3, CN o OH; cáda m y n es 0 o 1, siempre que m+n sea 1 o 2, y siempre que también cada m o n sea 0 cuando los miembros adyacentes en el anillo del anillo E sean S u O; R1a y R1b son iguales o diferentes y cada uno es hidrogeno o un sustituyente R10; o R1a y R1b junto con los átomos de carbono o heteroatomos a los que están unidos forman un anillo arilo o heteroarilo de 5 o 6 miembros, donde el anillo arilo o heteroarilo se sustituye opcionalmente con uno más sustituyentes R10; y R2, R3, R4, R5, R7, R8, y R10 son como se los define en las reivindicaciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87138606P | 2006-12-21 | 2006-12-21 | |
GB0625668A GB0625668D0 (en) | 2006-12-21 | 2006-12-21 | Pharmaceutical compounds |
US98263307P | 2007-10-25 | 2007-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30830A1 true UY30830A1 (es) | 2008-07-31 |
Family
ID=39283821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30830A UY30830A1 (es) | 2006-12-21 | 2007-12-21 | Piperidinas sustituidas que presentan actividad inhibitoria de proteinquinasa |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100093748A1 (es) |
EP (1) | EP2125805A1 (es) |
JP (1) | JP2010514675A (es) |
AR (1) | AR064416A1 (es) |
CL (1) | CL2007003791A1 (es) |
PE (1) | PE20081534A1 (es) |
TW (1) | TW200833676A (es) |
UY (1) | UY30830A1 (es) |
WO (1) | WO2008075109A1 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
UA99284C2 (ru) * | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
MY150059A (en) | 2007-10-11 | 2013-11-29 | Astrazeneca Ab | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors |
NZ588353A (en) * | 2008-04-21 | 2011-10-28 | Lexicon Pharmaceuticals Inc | Limk2 inhibitors, compositions comprising them, and methods of their use |
CN102209539B (zh) * | 2008-11-11 | 2013-06-12 | 伊莱利利公司 | P70 s6激酶抑制剂和mtor抑制剂的组合治疗剂 |
MX2011005002A (es) * | 2008-11-11 | 2011-05-25 | Lilly Co Eli | Inhibidor de p70 s6 quinasa y terapia de combinacion de inhibidor del receptor de egfr. |
AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
WO2011050016A1 (en) | 2009-10-23 | 2011-04-28 | Eli Lilly And Company | Akt inhibitors |
WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Npy y5受容体拮抗作用を有するヘテロ環誘導体 |
EP2621913B1 (en) | 2010-10-01 | 2014-11-19 | Bristol-Myers Squibb Company | Substituted benzimidazole and imidazopyridine compounds useful as cyp17 modulators |
CN103328473A (zh) | 2010-11-12 | 2013-09-25 | 百时美施贵宝公司 | 取代的氮杂吲唑化合物 |
EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
WO2012098217A1 (en) * | 2011-01-21 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders |
EP2694056B1 (en) | 2011-04-01 | 2019-10-16 | AstraZeneca AB | Therapeutic treatment |
US20140113824A1 (en) | 2011-05-10 | 2014-04-24 | Bayer Intellectual Property Gmbh | Bicyclic (thio)carbonylamidines |
SI2755965T1 (sl) * | 2011-09-12 | 2017-12-29 | Merck Patent Gmbh | Novi imidazolni amidi kot modulatorji kinazne aktivnosti |
EP2760870B1 (en) | 2011-09-27 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
WO2013079964A1 (en) | 2011-11-30 | 2013-06-06 | Astrazeneca Ab | Combination treatment of cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
EP2920178B1 (en) | 2012-11-16 | 2016-12-21 | Merck Patent GmbH | Novel heterocyclic derivatives as modulators of kinase activity (p70s6 and akt) |
JP6280130B2 (ja) | 2012-11-16 | 2018-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体 |
EP2970201B1 (en) | 2013-03-11 | 2019-06-19 | Merck Patent GmbH | 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP6588924B2 (ja) * | 2014-04-25 | 2019-10-09 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | ルテニウムの触媒作用によってアニリド類からビフェニルアミン類を製造する方法 |
CZ306987B6 (cs) * | 2015-10-26 | 2017-11-01 | Ústav experimentální botaniky AV ČR, v. v. i. | 2,6-disubstituované puriny pro použití jako léčiva a farmaceutické přípravky je obsahující |
CN109476669A (zh) * | 2016-05-18 | 2019-03-15 | 富荣吉有限责任公司 | Lim激酶抑制剂 |
MA45048A (fr) * | 2016-05-20 | 2019-03-27 | Taiho Pharmaceutical Co Ltd | Nouveau dérivé de 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one |
US20230148417A1 (en) | 2020-03-17 | 2023-05-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof |
CN113444110B (zh) * | 2020-03-25 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
TW202328138A (zh) | 2021-09-17 | 2023-07-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 稠合二環類衍生物的可藥用鹽、晶型及其製備方法 |
TW202342477A (zh) * | 2022-03-01 | 2023-11-01 | 香港商英矽智能科技知識產權有限公司 | 二醯基甘油激酶(DGK) α抑制劑及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
US20070208053A1 (en) * | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
-
2007
- 2007-12-18 AR ARP070105691A patent/AR064416A1/es unknown
- 2007-12-19 TW TW096148755A patent/TW200833676A/zh unknown
- 2007-12-20 JP JP2009542236A patent/JP2010514675A/ja active Pending
- 2007-12-20 WO PCT/GB2007/050776 patent/WO2008075109A1/en active Application Filing
- 2007-12-20 EP EP07848736A patent/EP2125805A1/en not_active Withdrawn
- 2007-12-21 UY UY30830A patent/UY30830A1/es not_active Application Discontinuation
- 2007-12-21 CL CL200703791A patent/CL2007003791A1/es unknown
- 2007-12-21 US US12/520,303 patent/US20100093748A1/en not_active Abandoned
-
2008
- 2008-01-02 PE PE2008000027A patent/PE20081534A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20100093748A1 (en) | 2010-04-15 |
PE20081534A1 (es) | 2008-12-19 |
JP2010514675A (ja) | 2010-05-06 |
AR064416A1 (es) | 2009-04-01 |
CL2007003791A1 (es) | 2008-08-22 |
EP2125805A1 (en) | 2009-12-02 |
TW200833676A (en) | 2008-08-16 |
WO2008075109A1 (en) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30830A1 (es) | Piperidinas sustituidas que presentan actividad inhibitoria de proteinquinasa | |
CO2018011825A2 (es) | Compuestos heteroaril-1,2,4-triazol y heteroaril-tetrazol | |
CU20130080A7 (es) | Derivados bicíclicos sustituidos para el tratamiento del sida | |
PE20181145A1 (es) | Compuestos de piridina | |
AR117916A1 (es) | Compuesto heterocíclico y su uso | |
CR20160548A (es) | Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1 | |
PE20211779A1 (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
CO2017003132A2 (es) | Inhibidores de la aldosterona sintasa derivados de la 2,6-diazaspiro[3.3]heptán-6-il]-3-piridil]isoindolín-1-ona o 2,7-diazaspiro[3.5]nonán-2-il]-3-piridil]isoindolín-1-ona | |
ECSP13012405A (es) | Compuestos heterocíclicos fusionados | |
PE20121358A1 (es) | Derivados de indol como inhibidores itk | |
DOP2010000068A (es) | Derivados de pirazol sustituidos | |
UY36101A (es) | Herbicidas de piridazinona | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
ECSP088805A (es) | 2-(piridin-2-il)-pirimidinas como fungicidas | |
UY32417A (es) | Compuestos de piridazinona | |
ECSP11011318A (es) | Derivados de benzofurano | |
AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
AR070264A1 (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos | |
MY169179A (en) | Novel piperidine compound or salt thereof | |
AR111307A1 (es) | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa | |
PA8776401A1 (es) | Nuevos compuestos hetericiclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos | |
NI201200095A (es) | Derivados de piridino - piridinonas, su preparación y su aplicación en terapéutica | |
AR096040A1 (es) | Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b | |
CO6362013A2 (es) | Derivados de rifamicina | |
UY36743A (es) | Nuevos 3-fenil-pirrolidin-2,4-diona alquinil-sustuidos y sus usos como herbicidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20170728 |